Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial

Atherosclerosis

Volumn 249, Issue , 2016, Pages 36-43

  Ishibashi, Shun ^a   Yamashita, Shizuya ^b,c   Arai, Hidenori ^d   Araki, Eiichi ^e   Yokote, Koutaro ^f   Suganami, Hideki ^g   Fruchart, Jean Charles ^h   Kodama, Tatsuhiko ⁱ  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Rinku General Medical Center   (Japan)

^d NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^e KUMAMOTO UNIVERSITY   (Japan)

^f CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g KOWA COMPANY LTD   (Japan)

^h Fondation coeur et arteres   (France)

ⁱ UNIVERSITY OF TOKYO   (Japan)

Author keywords

Dyslipidaemia; HDL; K 877; Pemafibrate; SPPARM ; Triglyceride

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN C; CHYLOMICRON; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PEMAFIBRATE; PLACEBO; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; BENZOXAZOLE DERIVATIVE; BUTYRIC ACID DERIVATIVE; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; K-877 COMPOUND; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA;

ADULT; ALLERGY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PARALLEL DESIGN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; TRIACYLGLYCEROL BLOOD LEVEL; AGED; AGONISTS; BLOOD; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; JAPAN; PATIENT SAFETY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BENZOXAZOLES; BUTYRATES; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; DYSLIPIDEMIAS; FEMALE; FENOFIBRATE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; JAPAN; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; PATIENT SAFETY; PPAR ALPHA; TRIGLYCERIDES;

EID: 84962418519     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2016.02.029     Document Type: Article

References (24)

1. World Health Organization cardiovascular disease statistics. http://www.who.int/mediacentre/factsheets/fs317/en/index.htm.
2. Stone N.J., Robinson J.G., Lichtenstein A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J. Am. Coll. Cardiol. 2014, 63:2889-2934.
3. Cholesterol Treatment Trialists C, Fulcher J., O'Connell R., et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015, 385:1397-1405.
4. Chapman M.J., Redfern J.S., McGovern M.E., Giral P. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol. Ther. 2010, 126:314-345.
5. European Association for Cardiovascular P, Rehabilitation, Reiner Z., et al. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur. Heart J. 2011, 32:1769-1818.
6. Group A.S., Ginsberg H.N., Elam M.B., et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N. Engl. J. Med. 2010, 362:1563-1574.
7. Jun M., Foote C., Lv J., et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010, 375:1875-1884.
8. Staels B., Dallongeville J., Auwerx J., et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998, 98:2088-2093.
9. Fruchart J.C. Peroxisome proliferator-activated receptor-α (PPARα): at the crossroads of obesity, diabetes and cardiovascular disease. Atherosclerosis 2009, 205:1-8.
10. Fruchart J.C. Selective peroxisome proliferator-activated receptor α modulators (SPPARMα): the next generation of peroxisome proliferator-activated receptor α-agonists. Cardiovasc Diabetol. 2013, 12:82.
11. Yamazaki Y., Abe K., Toma T., et al. Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor α agonists. Bioorg. Med. Chem. Lett. 2007, 17:4689-4693.
12. Usui S., Hara Y., Hosaki S., Okazaki M. A new on-line dual enzymatic method for simultaneous quantification of cholesterol and triglycerides in lipoproteins by HPLC. J. Lipid Res. 2002, 43:805-814.
13. Khetarpal S.A., Rader D.J. Triglyceride-rich lipoproteins and coronary artery disease risk: new insights from human genetics. Arterioscler. Thromb. Vasc. Biol. 2015, 35:e3-9.
14. Varbo A., Benn M., Tybjaerg-Hansen A., et al. Remnant cholesterol as a causal risk factor for ischemic heart disease. J. Am. Coll. Cardiol. 2013, 61:427-436.
15. Raza-Iqbal S., Tanaka T., Anai M., et al. Transcriptome analysis of K-877 (a novel selective PPARα modulator (SPPARMα))-regulated genes in primary human hepatocytes and the mouse liver. J. Atheroscler. Thromb. 2015, 22:754-772.
16. Nissen S.E., Nicholls S.J., Wolski K., et al. Effects of a potent and selective PPAR-α agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials. JAMA 2007, 297:1362-1373.
17. Sigurdsson G., Nicoll A., Lewis B. Conversion of very low density lipoprotein to low density lipoprotein. A metabolic study of apolipoprotein B kinetics in human subjects. J. Clin. Invest. 1975, 56:1481-1490.
18. Martin S.S., Khokhar A.A., May H.T., et al. HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the lipoprotein investigators collaborative. Eur. Heart J. 2015, 36:22-30.
19. Inagaki T., Dutchak P., Zhao G., et al. Endocrine regulation of the fasting response by PPARα-mediated induction of fibroblast growth factor 21. Cell Metab. 2007, 5:415-425.
20. Galman C., Lundasen T., Kharitonenkov A., et al. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARα activation in man. Cell Metab. 2008, 8:169-174.
21. Ong K.L., Rye K.A., O'Connell R., et al. Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetes. J. Clin. Endocrinol. Metab. 2012, 97:4701-4708.
22. Keech A., Simes R.J., Barter P., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366:1849-1861.
23. de Lorgeril M., Salen P., Paillard F., et al. Lipid-lowering drugs and homocysteine. Lancet 1999, 353:209-210.
24. Staels B., Rubenstrunk A., Noel B., et al. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor α/δ agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology 2013, 58:1941-1952.